Commentary: Theoretical Predictions of Flow Effects on Intestinal and Systemic Availability in Physiologically Based Pharmacokinetic Intestine Models: The Traditional Model, Segregated Flow Model, and QGut Model
Authors:
- 1 October 2012
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 40 (10) , 1869-1877
Abstract
Physiologically based pharmacokinetic (PBPK) models for the intestine, comprising of different flow rates perfusing the enterocyte region, were revisited for appraisal of flow affects on the intestinal availability (FI) and, in turn, the systemic availability (Fsys) and intestinal versus liver contribution to the first-pass effect during oral drug absorption. The traditional model (TM), segregated flow model (SFM), and effective flow (QGut) model stipulate that 1.0, ∼0.05 to 0.3, and ≤0.484× of the total intestinal flow, respectively, reach the enterocyte region that houses metabolically active and transporter-enriched enterocytes. The fractional flow rate to the enterocyte region (fQ), when examined under varying experimental conditions, was found to range from 0.024 to 0.2 for the SFM and 0.065 to 0.43 for the QGut model. Appraisal of these flow intestinal models, when used in combination with whole-body PBPK models, showed the ranking as SFM < QGut model < TM in the description of FI, and the same ranking existed for the contribution of the intestine to first-pass removal. However, the ranking for the predicted contribution of hepatic metabolism, when present, to first-pass removal was the opposite: SFM > QGut model > TM. The findings suggest that the fQ value strongly influences the rate of intestinal metabolism (FI and Fsys) and indirectly affects the rate of liver metabolism due to substrate sparing effect. Thus, the fQ value in the intestinal flow models pose serious implications on the interpretation of data on the first-pass effect and oral absorption of drugs.Keywords
This publication has 53 references indexed in Scilit:
- In SilicoModeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 SubstrateMolecular Pharmaceutics, 2012
- A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite PairDrug Metabolism and Disposition, 2012
- Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout MouseDrug Metabolism and Disposition, 2011
- The Role of Small-Intestinal P450 Enzymes in Protection against Systemic Exposure of Orally Administered Benzo[a]PyreneThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by ClarithromycinDrug Metabolism and Disposition, 2010
- Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human IntestineThe AAPS Journal, 2009
- MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES)Drug Metabolism and Disposition, 2003
- Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in ratXenobiotica, 2002
- Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shuntsHepatology, 2001
- Sequential first-pass elimination of a metabolite derived from a precursorJournal of Pharmacokinetics and Biopharmaceutics, 1979